Obesity and GLP-1 Drugs

A Mayo Clinic observational study published in The Lancet Obstetrics, Gynaecology & Women's Health reports that postmenopausal women with overweight or obesity lost about 35% more weight when menopausal hormone therapy was used alongside the GLP‑1–based drug tirzepatide than when taking tirzepatide alone. Researchers reviewed 120 women treated for at least 12 months: 40 on both hormone therapy and tirzepatide lost an average of 19.2% of their body weight, compared with 14.0% in 80 women on tirzepatide without hormones, and more in the hormone group hit higher weight‑loss thresholds. The authors and outside endocrinologists stress the study is observational and cannot prove hormone therapy caused the extra weight loss, noting women who elect estrogen therapy may be healthier, more adherent to diet and exercise, or benefit from symptom relief that improves sleep and activity. Preclinical data suggest estrogen could biologically enhance GLP‑1 drugs’ appetite‑suppressing effects, but that mechanism remains unproven in humans and will require randomized trials. The findings arrive amid surging U.S. use of GLP‑1 medications and intense public interest—reflected in social media debates—over how midlife hormone changes, menopause care, and expensive obesity drugs intersect in real‑world treatment decisions and long‑term cardiometabolic risk.